Alvotech shares rose nearly 10% after its new drug, AVT80, cleared key safety and effectiveness tests. The drug is a cheaper biosimilar version of Entyvio, a medicine for stomach-related diseases that generated $6.4 billion in sales last year. The results allow Alvotech to seek government approval to begin commercial sales.